Identifying high-risk stage IIIA cutaneous melanoma patients who might benefit from adjuvant therapy: the importance of micrometastatic tumor burden
Ann Transl Med
.
2023 Aug 30;11(10):371.
doi: 10.21037/atm-23-597.
Epub 2023 Mar 3.
Author
Michael E Egger
1
Affiliation
1
Hiram C. Polk, Jr., MD, Department of Surgery, University of Louisville, Louisville, KY, USA.
PMID:
37675308
PMCID:
PMC10477633
DOI:
10.21037/atm-23-597
No abstract available
Keywords:
Adjuvant therapy melanoma; IIIA melanoma; micrometastatic tumor burden.
Publication types
Editorial
Comment